Sichenzia Ross Ference Kesner LLP Represents MabVax Therapeutics Holdings, Inc. on $4.1 Million Public Offering
Press Release – New York, NY – June 5, 2017 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, in a public offering of common stock and Series G Preferred Stock for a total of $4.1 million. Sold in the offering was a combination of common stock and Series G Preferred Stock at $1.75 per share of common stock and Series G Preferred Stock.
The Sichenzia Ross Ference Kesner LLP team was led by partners Harvey Kesner, Avital Perlman and Tara Guarneri-Ferrara and associate Evan Berger.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- 加州新商业融资披露立法 - September 28, 2018
- Sichenzia Ross Ference LLP宣布推出新的Web域名 - September 26, 2018
- Sichenzia Ross Ference LLP Represents AIT Therapeutics, Inc. in $20,000,000 Line of Credit - September 6, 2018